Dr Reddy's launches generic cancer drug in India

Dr Reddy's Laboratories on Monday said it has launched blood cancer drug Invista in the country. The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories said in a statement.

Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.

Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML).

CML is a type of blood-cell cancer that begins in the bone marrow.

The median age of the patients in India is a decade earlier than the west, and every year about nine thousand new patients are diagnosed in the country.

"The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India," Dr Reddy's Laboratories CEO, Branded Markets (India and Emerging Markets), M V Ramana said.

Source:https://www.moneycontrol.com/news/business/dr-reddys-launches-generic-cancer-drug-in-india-5138521.html

Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types

Image
Bristol-Myers Squibb Company  (NYSE:BMY) and  Clovis Oncology, Inc. (Nasdaq:CLVS) announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy  Opdivo   and Clovis Oncology’s poly (ADP-ribose) polymerase (PARP) inhibitor  Rubraca  in pivotal phase 3 clinical trials in: Advanced ovarian cancer : First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Advanced triple-negative breast cancers  (TNBC): First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD). The collaboration will also include a Phase 2 study to e
Read more